In the News
Media Releases
Proprietary Cannabis Growing Technology
ABcann Medicinals Inc. was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations..New marijuana entrant ABcann aiming for consistency in products
ABcann Global, a Canadian licensed medical marijuana producer, began trading on the Venture in May. We check in with Aaron Keay, CEO with ABcann Global, on how the company intends to scale up production.CFN Interview with ABcann Medicinals
Interview with Aaron KeayABcann Global Corporation Opens Toronto Stock Market
Ken Clement, Founder and Executive Chair and Aaron Keay, CEO, ABcann Global Corporation (ABCN), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange to open the market. ABcann Global is licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR).The strategic approach of ABcann’s growth technique
In this interview, Aaron Keay, CEO of ABcann Global Corporation, speaks with Natasha Frakes about why the company waited two years from getting their license before going public, the factors that differentiate the company from competitors, as well as their strategy in the Canadian marketplace. Aaron discusses how the company manages the health of its plants in order to ensure that deviation and variance in the product is minimal.Licensed producers negotiate learning curve to deliver consistent medical marijuana product
ABcann’s growing reputation for quality is opening doors abroad In Canada’s blossoming medical marijuana market, the field is rapidly becoming crowded.One Of The Earliest Licensed Medical Marijuana Producers
The growing cannabis sector is here to stay. We initiated on ABcann in May of this year. We really like the company for a few reasons, one they were one of the earliest licensed producers in the sector secondly, they’ve got a top-notch management team and lastly, their capacity potential.Canadian Cannabis Facility Tours - ABcann Medicinals
Situated in Napanee, Ontario, ABcann’s belief is that clients deserve access to standardized medical cannabis that contributes to a balanced lifestyle. Our flagship facility contains exclusive plant growing technology combining together the concepts, systems and components to formulate a pharmaceutical grade, plant based medicine through standardization.ABcann Global Enters Its Growth Phase
CFN Media recently interviewed former CEO Aaron Keay to discuss the company’s transition and its long-term goals in the spaceABcann aiming for Consistency
ABcann Global, a Canadian licensed medical marijuana producer, began trading on the Venture in May. We check in with Aaron Keay, CEO with ABcann Global, on how the company intends to scale up production.ABcann & Cannabis Wheaton Sign Win-Win Deal to Expand Production
CFN Media Group today announced publication of an article covering ABcann Global Corp.'s binding interim agreement with Cannabis Wheaton Income Corp.Time to Invest in ABcann Global (TSX-V: ABCN)
Some said it would be the biggest legal cannabis IPO of the year...ABcann’s Pesticide-Free Approach is a Breath of Fresh Air
The industry continues to struggle with safety concerns, such as the use of banned pesticides...Boom Time Ahead For Licensed Producers Of Medical Marijuana
ABcann Medicinals, one of Canada's first medical-marijuana producers to be licensed under federal regulations, is going public.Pharmaceutical Grade, Standardized Licensed Producer Poised to Go Public
Canada's legal cannabis industry could generate $22.6 billion in annual revenue, which has created significant opportunities for investors...Cannabis Producer Growing
A Napanee company taking a high-tech approach to producing medical cannabis is going public in an effort to finance its rapid expansion...CANNA FARMS WINS TOP REVIEWED LICENSED PRODUCER OF THE YEAR AWARD
VIVO Cannabis™ Reports Record Revenue for Q3 2018
Harvest Medicine Launches Free Medical Cannabis Telemedicine Platform
VIVO Announces Initial $5 Million Strategic Investment in National Access Cannabis
Harvest Medicine Continues National Expansion with Acquisition of Trauma Healing Centres
VIVO AND LOYALIST COLLEGE COLLABORATE ON CANNABIS APPLIED RESEARCH PROJECT
VIVO Partners with Pharmascience to Develop Novel Cannabis Products
VIVO Announces $5 million Strategic Investment and Supply Agreement with Westleaf
VIVO selects Green Hedge as Distribution Partner for Adult-Use Products
VIVO Cannabis Inc. Upgrades to the OTCQX Best Market
VIVO Completes First New Seasonal Greenhouse
Canna Farms Completes First Shipment of Recreational Cannabis
VIVO Cannabis Completes Acquisition of Canna Farms
VIVO Cannabis Releases Q2 2018 Results and Provides Business Update
VIVO Cannabis Selected as a Supplier to Ontario Retail Cannabis Market
ABcann Global Announces Company Name Change to VIVO Cannabis™
ABcann Introduces Lumina, a Cannabis Brand Focused on Wellness
Analyst Call re Canna Farms acquisition
ABcann to Acquire Leading B.C. Producer Canna Farms
ABcann Launches FIRESIDE, a Premium Line of Recreational Cannabis
ABcann Selected as a Supplier to Alberta Retail Cannabis Market
Harvest Medicine Surpasses 15,000 Patient Milestone in under 18 Months of Operation
ABcann Global Announces Results of Annual General Meeting
ABcann Launches Beacon Medical
ABcann Provides Business Update
Choom™ and ABcann Announce Strategic Investment and Supply Agreement
ABCANN ANNOUNCES RESIGNATION OF FOUNDING DIRECTOR KEN CLEMENT
ABCANN RETAINS VIRTUE AS AGENCY OF RECORD
ABCANN GLOBAL PROVIDES BUSINESS UPDATE
ABCANN GLOBAL CORPORATION ANNOUNCES FILING OF FINAL PROSPECTUS
ABCANN COMPLETES ACQUISITION OF HARVEST MEDICINE
ABCANN GLOBAL CORPORATION ANNOUNCES $70 MILLION BOUGHT DEAL FINANCING
ABCANN GRANTED AUSTRALIAN IMPORT LICENSE
ABCANN APPOINTS NEW CHIEF MARKETING OFFICER
ABCANN GLOBAL ANNOUNCES RECEIPT OF HEALTH CANADA LICENSE TO PRODUCE CANNABIS OILS
ABcann Enters into Agreement to Acquire Leading Medical Cannabis Clinic
ABcann Global Announces Financial Results and Provides Operational Update
ABcann Global Announces $30 Million Debenture Financing
ABcann Global Strengthens Board and Executive Team
ABcann Global Appoints New Independent Chair
ABcann Global Receives $11.9 Million from Exercise of Warrants
ABcann Global Appoints Barry Fishman as Chief Executive Officer
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
ABcann Global files Q2 2017 Financial Results and Provides Operational Update
Management’s Discussion and Analysis
ABcann RELEASES HIGH LEVEL CBD PRODUCT AND LAUNCHES INITIAL OILS STRATEGY
ABcann GLOBAL PROVIDES CONSTRUCTION AND EXPANSION UPDATE
ABcann GLOBAL ANNOUNCES LISTING ON THE OTCQB MARKETPLACE AND THE FRANKFURT STOCK EXCHANGE
ABcann AND CANNABIS WHEATON ANNOUNCE SIGNING OF AGREEMENT FOR FIRST TRANCHE $15 MILLION INVESTMENT
ABcann GLOBAL ANNOUNCES INCLUSION ON THE HORIZONS MEDICAL MARIJUANA LIFE SCIENCES ETF
ABcann GLOBAL RECRUITS DR. MICHAEL SHANNON AS CHIEF MEDICAL CONSULTANT
ABcann GLOBAL EXTENDS RESEARCH AGREEMENT WITH THE UNIVERSITY OF GUELPH
ABcann GLOBAL ANNOUNCES APPOINTMENT OF W. BRETT WILSON TO ADVISORY BOARD
PANDA AND ABcann MEDICINALS ANNOUNCE MULTI-STAGE PRODUCT TESTING METHODOLOGY
PANDA AND ABcann MEDICINALS ANNOUNCE CONDITIONAL APPROVAL OF QUALIFYING TRANSACTION
PANDA ANNOUNCES PROPOSED QUALIFYING TRANSACTION WITH ABcann MEDICINALS INC